Pacific Biosciences of California, Inc. (NASDAQ:PACB) is scheduled to post its quarterly earnings results after the market closes on Tuesday, October 31st. Analysts expect Pacific Biosciences of California to post earnings of ($0.22) per share for the quarter.
Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $20.07 million for the quarter, compared to analyst estimates of $23.34 million. Pacific Biosciences of California had a negative return on equity of 93.31% and a negative net margin of 89.67%. The firm’s revenue was down 3.2% on a year-over-year basis. During the same period last year, the business earned ($0.21) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-0.89 EPS for the current fiscal year and $-0.64 EPS for the next fiscal year.
Shares of Pacific Biosciences of California, Inc. (NASDAQ PACB) opened at 4.25 on Friday. The firm’s market capitalization is $491.26 million. The company’s 50-day moving average price is $4.92 and its 200 day moving average price is $4.19. Pacific Biosciences of California, Inc. has a 12-month low of $3.08 and a 12-month high of $8.57.
TRADEMARK VIOLATION NOTICE: “Pacific Biosciences of California, Inc. (PACB) Scheduled to Post Earnings on Tuesday” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/29/pacific-biosciences-of-california-inc-pacb-scheduled-to-post-earnings-on-tuesday.html.
Several research firms have commented on PACB. CL King downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price objective for the company. in a research note on Thursday, September 28th. BidaskClub downgraded Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 27th. Finally, Zacks Investment Research downgraded Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Pacific Biosciences of California currently has a consensus rating of “Hold” and a consensus price target of $8.93.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.
Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.